The global lung cancer therapeutics market size is accounted at USD 35.37 billion in 2025 and is forecasted to hit around USD 71.30 billion by 2034, representing a CAGR of 8.10% from 2025 to 2034. The North America market size was estimated at USD 10.14 billion in 2024 and is expanding at a CAGR of 8.11% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Lung Cancer Therapeutics Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Lung Cancer Therapeutics Market, by Therapy Type
8.1.1. Radiation Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Targeted Therapy
8.1.2.1. Market Revenue and Forecast
8.1.3. Immunotherapy
8.1.3.1. Market Revenue and Forecast
8.1.4. Chemotherapy
8.1.4.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
9.1. Lung Cancer Therapeutics Market, by Lung Cancer Type
9.1.1. Small Cell Lung Cancer
9.1.1.1. Market Revenue and Forecast
9.1.2. Non-small Cell Lung Cancer
9.1.2.1. Market Revenue and Forecast
9.1.3. Lung Carcinoid Tumor
9.1.3.1. Market Revenue and Forecast
10.1. Lung Cancer Therapeutics Market, by Distribution Channel Type
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast
11.1. Lung Cancer Therapeutics Market, by Type of Molecule
11.1.1. Small molecules
11.1.1.1. Market Revenue and Forecast
11.1.2. Biologics
11.1.2.1. Market Revenue and Forecast
12.1. Lung Cancer Therapeutics Market, by Drug Class
12.1.1. Alkylating Agents
12.1.1.1. Market Revenue and Forecast
12.1.2. Antimetabolites
12.1.2.1. Market Revenue and Forecast
12.1.3. Multikinase Inhibitors
12.1.3.1. Market Revenue and Forecast
12.1.4. Mitotic Inhibitors
12.1.4.1. Market Revenue and Forecast
12.1.5. EGFR Inhibitors
12.1.5.1. Market Revenue and Forecast
12.1.6. Others
12.1.6.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Therapy
13.1.2. Market Revenue and Forecast, by Lung Cancer
13.1.3. Market Revenue and Forecast, by Distribution Channel
13.1.4. Market Revenue and Forecast, by Type of Molecule
13.1.5. Market Revenue and Forecast, by Drug Class
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Therapy
13.1.6.2. Market Revenue and Forecast, by Lung Cancer
13.1.6.3. Market Revenue and Forecast, by Distribution Channel
13.1.6.4. Market Revenue and Forecast, by Type of Molecule
13.1.7. Market Revenue and Forecast, by Drug Class
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Therapy
13.1.8.2. Market Revenue and Forecast, by Lung Cancer
13.1.8.3. Market Revenue and Forecast, by Distribution Channel
13.1.8.4. Market Revenue and Forecast, by Type of Molecule
13.1.8.5. Market Revenue and Forecast, by Drug Class
13.2. Europe
13.2.1. Market Revenue and Forecast, by Therapy
13.2.2. Market Revenue and Forecast, by Lung Cancer
13.2.3. Market Revenue and Forecast, by Distribution Channel
13.2.4. Market Revenue and Forecast, by Type of Molecule
13.2.5. Market Revenue and Forecast, by Drug Class
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Therapy
13.2.6.2. Market Revenue and Forecast, by Lung Cancer
13.2.6.3. Market Revenue and Forecast, by Distribution Channel
13.2.7. Market Revenue and Forecast, by Type of Molecule
13.2.8. Market Revenue and Forecast, by Drug Class
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Therapy
13.2.9.2. Market Revenue and Forecast, by Lung Cancer
13.2.9.3. Market Revenue and Forecast, by Distribution Channel
13.2.10. Market Revenue and Forecast, by Type of Molecule
13.2.11. Market Revenue and Forecast, by Drug Class
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Therapy
13.2.12.2. Market Revenue and Forecast, by Lung Cancer
13.2.12.3. Market Revenue and Forecast, by Distribution Channel
13.2.12.4. Market Revenue and Forecast, by Type of Molecule
13.2.13. Market Revenue and Forecast, by Drug Class
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Therapy
13.2.14.2. Market Revenue and Forecast, by Lung Cancer
13.2.14.3. Market Revenue and Forecast, by Distribution Channel
13.2.14.4. Market Revenue and Forecast, by Type of Molecule
13.2.15. Market Revenue and Forecast, by Drug Class
13.3. APAC
13.3.1. Market Revenue and Forecast, by Therapy
13.3.2. Market Revenue and Forecast, by Lung Cancer
13.3.3. Market Revenue and Forecast, by Distribution Channel
13.3.4. Market Revenue and Forecast, by Type of Molecule
13.3.5. Market Revenue and Forecast, by Drug Class
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Therapy
13.3.6.2. Market Revenue and Forecast, by Lung Cancer
13.3.6.3. Market Revenue and Forecast, by Distribution Channel
13.3.6.4. Market Revenue and Forecast, by Type of Molecule
13.3.7. Market Revenue and Forecast, by Drug Class
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Therapy
13.3.8.2. Market Revenue and Forecast, by Lung Cancer
13.3.8.3. Market Revenue and Forecast, by Distribution Channel
13.3.8.4. Market Revenue and Forecast, by Type of Molecule
13.3.9. Market Revenue and Forecast, by Drug Class
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Therapy
13.3.10.2. Market Revenue and Forecast, by Lung Cancer
13.3.10.3. Market Revenue and Forecast, by Distribution Channel
13.3.10.4. Market Revenue and Forecast, by Type of Molecule
13.3.10.5. Market Revenue and Forecast, by Drug Class
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Therapy
13.3.11.2. Market Revenue and Forecast, by Lung Cancer
13.3.11.3. Market Revenue and Forecast, by Distribution Channel
13.3.11.4. Market Revenue and Forecast, by Type of Molecule
13.3.11.5. Market Revenue and Forecast, by Drug Class
13.4. MEA
13.4.1. Market Revenue and Forecast, by Therapy
13.4.2. Market Revenue and Forecast, by Lung Cancer
13.4.3. Market Revenue and Forecast, by Distribution Channel
13.4.4. Market Revenue and Forecast, by Type of Molecule
13.4.5. Market Revenue and Forecast, by Drug Class
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Therapy
13.4.6.2. Market Revenue and Forecast, by Lung Cancer
13.4.6.3. Market Revenue and Forecast, by Distribution Channel
13.4.6.4. Market Revenue and Forecast, by Type of Molecule
13.4.7. Market Revenue and Forecast, by Drug Class
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Therapy
13.4.8.2. Market Revenue and Forecast, by Lung Cancer
13.4.8.3. Market Revenue and Forecast, by Distribution Channel
13.4.8.4. Market Revenue and Forecast, by Type of Molecule
13.4.9. Market Revenue and Forecast, by Drug Class
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Therapy
13.4.10.2. Market Revenue and Forecast, by Lung Cancer
13.4.10.3. Market Revenue and Forecast, by Distribution Channel
13.4.10.4. Market Revenue and Forecast, by Type of Molecule
13.4.10.5. Market Revenue and Forecast, by Drug Class
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Therapy
13.4.11.2. Market Revenue and Forecast, by Lung Cancer
13.4.11.3. Market Revenue and Forecast, by Distribution Channel
13.4.11.4. Market Revenue and Forecast, by Type of Molecule
13.4.11.5. Market Revenue and Forecast, by Drug Class
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Therapy
13.5.2. Market Revenue and Forecast, by Lung Cancer
13.5.3. Market Revenue and Forecast, by Distribution Channel
13.5.4. Market Revenue and Forecast, by Type of Molecule
13.5.5. Market Revenue and Forecast, by Drug Class
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Therapy
13.5.6.2. Market Revenue and Forecast, by Lung Cancer
13.5.6.3. Market Revenue and Forecast, by Distribution Channel
13.5.6.4. Market Revenue and Forecast, by Type of Molecule
13.5.7. Market Revenue and Forecast, by Drug Class
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Therapy
13.5.8.2. Market Revenue and Forecast, by Lung Cancer
13.5.8.3. Market Revenue and Forecast, by Distribution Channel
13.5.8.4. Market Revenue and Forecast, by Type of Molecule
13.5.8.5. Market Revenue and Forecast, by Drug Class
14.1. AstraZeneca
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. BoehringerIngelheim
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Bristol-Myers Squibb Company
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Eli Lilly and Company
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Hoffmann-La Roche
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Merck & Co
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Pfizer Inc.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Allergan Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Teva Pharmaceutical Industries Ltd.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Abbvie, Inc.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
14.11. Johnson & Johnson
14.11.1. Company Overview
14.11.2. Product Offerings
14.11.3. Financial Performance
14.11.4. Recent Initiatives
14.12. Amgen Inc.
14.12.1. Company Overview
14.12.2. Product Offerings
14.12.3. Financial Performance
14.12.4. Recent Initiatives
14.13. Novartis AG
14.13.1. Company Overview
14.13.2. Product Offerings
14.13.3. Financial Performance
14.13.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample